NURIX THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
NURIX THERAPEUTICS, INC. (NRIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 0.34% for the 12-month period ending 2020-11-30, per its 10-K filed 2021-02-16.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2021-02-16
- NURIX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2020 was 0.34%, a 76.06% decline from fiscal 2019.
- NURIX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2019 was 1.42%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|
| 2020-11-30 | 0.34% 10-K · filed 2021-02-16 |
| 2019-11-30 | 1.42% 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |